Menopur (Menotrophin)

Menotropin contains purified follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). These hormones bind to specific receptors on ovarian granulosa and theca cells, activating intracellular signalling pathways that promote follicular growth, estrogen production, and ovulation, while LH supports luteinisation and progesterone synthesis.

The dose of Menopur is individualized by the treating physician based on the patient’s age, ovarian reserve, response to prior stimulation cycles, and the specific goals of the assisted reproduction protocol. The prescriber adjusts the amount and timing according to ultrasound and hormonal monitoring.

Menopur is not intended for use during an established pregnancy, and its safety in pregnancy has not been established. Women who become pregnant while on treatment should be managed by a specialist. Limited data are available for breastfeeding, so use is generally avoided unless the benefit outweighs potential risk.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and the necessary import documentation.

Menopur provides a fixed combination of FSH and LH activity, whereas some alternatives such as recombinant FSH contain only FSH. The presence of LH in Menopur can be advantageous for patients with a documented LH deficiency, but the choice depends on individual response, protocol design and physician preference.

Menopur should be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light. Do not freeze or shake the vial. Once reconstituted, the solution should be used within the time frame specified in the product label and kept refrigerated until administration.

Menopur is supplied as a powder for solution for injection. After reconstitution with the appropriate diluent, it is administered by a subcutaneous or intramuscular injection according to the dosing schedule prescribed by the fertility specialist, typically once daily during the stimulation phase.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause abdominal pain, fluid accumulation, and thromboembolic complications, as well as multiple pregnancy, ovarian torsion, and rare allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these occur.

Menopur should not be used in women with active ovarian cysts, uncontrolled thyroid disease, estrogen‑dependent tumours, severe ovarian failure, or known hypersensitivity to menotropin or any excipients. It is also contraindicated in patients who are pregnant, breastfeeding, or for whom assisted reproductive techniques are not indicated.